Durable response with lenvatinib and pembrolizumab combination therapy in a patient with pre-treated metastatic cholangiocarcinoma

Affiliations

• ¹ Department of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. . lena.dreikhausen@umm.de.
• ² Department of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim; Preventive Medicine Baden-Württemberg (CPMBW), Medical Faculty Mannheim, Heidelberg University, Germany. alexander.kusnik@umm.de.
• ³ Department of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. nadine.schulte@umm.de.
• ⁴ Department of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. m.eckardt@dkfz-heidelberg.de.
• ⁵ Department of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim; Preventive Medicine Baden-Württemberg (CPMBW), Medical Faculty Mannheim, Heidelberg University, Germany. andreas.teufel@umm.de.
• ⁶ Institute of Pathology, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. timo.gaiser@umm.de.
• ⁷ Department of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim; Preventive Medicine Baden-Württemberg (CPMBW), Medical Faculty Mannheim, Heidelberg University, Germany. matthias.ebert@umm.de.
• ⁸ Department of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. Tianzuo.Zhan@umm.de.